The health care implications were favourable towards managed-care companies and in the long term, potentially negative for drug and medical device makers counting on a boom in obesity-related conditions.
Analysts say the trend reminds them of 1990s-era managed-care strategies that helped constrain health spending, but that frustrated doctors and patients.